180 related articles for article (PubMed ID: 30947657)
61. Prognostic value of abnormally expressed lncRNAs in ovarian carcinoma: a systematic review and meta-analysis.
Luo P; Liu XF; Wang YC; Li ND; Liao SJ; Yu MX; Liang CZ; Tu JC
Oncotarget; 2017 Apr; 8(14):23927-23936. PubMed ID: 28118613
[TBL] [Abstract][Full Text] [Related]
62. Long Noncoding RNA MNX1-AS1 Knockdown Inhibits Cell Proliferation and Migration in Ovarian Cancer.
Lv Y; Li H; Li F; Liu P; Zhao X
Cancer Biother Radiopharm; 2017 Apr; 32(3):91-99. PubMed ID: 28414551
[TBL] [Abstract][Full Text] [Related]
63. Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer.
Chen T; Xie W; Xie L; Sun Y; Zhang Y; Shen Z; Sha N; Xu H; Wu Z; Hu H; Wu C
Biochem Biophys Res Commun; 2015 Dec; 468(4):666-70. PubMed ID: 26551459
[TBL] [Abstract][Full Text] [Related]
64. Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic lncRNA biomarkers in hepatocellular carcinoma.
Yan Y; Yu J; Liu H; Guo S; Zhang Y; Ye Y; Xu L; Ming L
Pathol Res Pract; 2018 Dec; 214(12):2031-2038. PubMed ID: 30316688
[TBL] [Abstract][Full Text] [Related]
65. The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Wambecke A; Ahmad M; Lambert B; Joly F; Poulain L; Denoyelle C; Meryet-Figuiere M
Gynecol Oncol; 2020 Mar; 156(3):726-733. PubMed ID: 31883617
[TBL] [Abstract][Full Text] [Related]
66. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1.
Liu E; Liu Z; Zhou Y
Int J Clin Exp Pathol; 2015; 8(4):3803-10. PubMed ID: 26097562
[TBL] [Abstract][Full Text] [Related]
67. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
68. Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma.
Zhang Z; Qian W; Wang S; Ji D; Wang Q; Li J; Peng W; Gu J; Hu T; Ji B; Zhang Y; Wang S; Sun Y
Cell Physiol Biochem; 2018; 49(5):1778-1791. PubMed ID: 30231249
[TBL] [Abstract][Full Text] [Related]
69. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
70. Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells.
Li Y; Huang S; Li Y; Zhang W; He K; Zhao M; Lin H; Li D; Zhang H; Zheng Z; Huang C
Tumour Biol; 2016 Oct; 37(10):14205-14215. PubMed ID: 27553025
[TBL] [Abstract][Full Text] [Related]
71. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
Wang J; Ye C; Liu J; Hu Y
Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
[TBL] [Abstract][Full Text] [Related]
72. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
Li SS; Ma J; Wong AST
J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
[TBL] [Abstract][Full Text] [Related]
73. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
Li N; Zhan X; Zhan X
Gynecol Oncol; 2018 Aug; 150(2):343-354. PubMed ID: 29921511
[TBL] [Abstract][Full Text] [Related]
74. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
75. CTD-2020K17.1, a Novel Long Non-Coding RNA, Promotes Migration, Invasion, and Proliferation of Serous Ovarian Cancer Cells In Vitro.
Zhu L; Guo Q; Lu X; Zhao J; Shi J; Wang Z; Zhou X
Med Sci Monit; 2018 Mar; 24():1329-1339. PubMed ID: 29504606
[TBL] [Abstract][Full Text] [Related]
76. Long non-coding RNAs in cancer drug resistance development.
Majidinia M; Yousefi B
DNA Repair (Amst); 2016 Sep; 45():25-33. PubMed ID: 27427176
[TBL] [Abstract][Full Text] [Related]
77. MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.
Ma Y; Lu Y; Lu B
Cancer Invest; 2016 Oct; 34(9):465-476. PubMed ID: 27673409
[TBL] [Abstract][Full Text] [Related]
78. Construction and analysis of lncRNA-lncRNA synergistic networks to reveal clinically relevant lncRNAs in cancer.
Li Y; Chen J; Zhang J; Wang Z; Shao T; Jiang C; Xu J; Li X
Oncotarget; 2015 Sep; 6(28):25003-16. PubMed ID: 26305674
[TBL] [Abstract][Full Text] [Related]
79. Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer.
Wang J; Cheng G; Li X; Pan Y; Qin C; Yang H; Hua L; Wang Z
Tumour Biol; 2016 Jul; 37(7):9603-13. PubMed ID: 26797783
[TBL] [Abstract][Full Text] [Related]
80. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis.
Shi XM; Teng F
Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
